Corticosteroid News and Research RSS Feed - Corticosteroid News and Research

Corticosteroids are any steroid hormones made in the adrenal cortex (the outer part of the adrenal gland). They are also made in the laboratory. Corticosteroids have many different effects in the body, and are used to treat many different conditions. They may be used as hormone replacement, to suppress the immune system, and to treat some side effects of cancer and its treatment. Corticosteroids are also used to treat certain lymphomas and lymphoid leukemias.

Mayo Clinic research shows RA patients more likely to develop chronic kidney disease

Rheumatoid arthritis patients are likelier than the average person to develop chronic kidney disease, and more severe inflammation in the first year of rheumatoid arthritis, corticosteroid use, high blood pressure and obesity are among the risk factors, new Mayo Clinic research shows. [More]

Research shows that rheumatoid arthritis patients are at higher risk of kidney disease

Rheumatoid arthritis patients are likelier than the average person to develop chronic kidney disease, and more severe inflammation in the first year of rheumatoid arthritis, corticosteroid use, high blood pressure and obesity are among the risk factors, new Mayo Clinic research shows. [More]
SIFI, NovaMedica agree to market eight products for treatment of ophthalmic pathologies in Russia

SIFI, NovaMedica agree to market eight products for treatment of ophthalmic pathologies in Russia

Leading Italian developer of innovative eye care solutions S.I.F.I. S.p.A. and Russian pharmaceutical company NovaMedica have entered into an exclusive commercial agreement for NovaMedica to market eight products developed and licensed by SIFI for the treatment of a wide range of ophthalmic pathologies in Russia and the CIS. [More]

Ocular Therapeutix starts Phase 3 clinical program to evaluate safety, efficacy of dexamethasone

Ocular Therapeutix, Inc. announces the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix's dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days. [More]

Knopp and NIAID collaborate to investigate eosinophil-lowering effects of dexpramipexole

Knopp Biosciences LLC today announced a second collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to investigate the eosinophil-lowering effects of the investigational drug dexpramipexole. [More]

Dr. Reddy's Laboratories launches Moxifloxacin Hydrochloride Tablets

Dr. Reddy's Laboratories Ltd. announced today that it has launched Moxifloxacin Hydrochloride Tablets, 400 mg, a therapeutic equivalent generic version of Avelox (moxifloxacin HCl) tablets 400 mg in the US market on March 04, 2014, following the approval by the United States Food & Drug Administration. [More]

Phase III studies show tiotropium delivered via Respimat inhaler proves effective in asthma patients

Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities. [More]

Ulcerative colitis patients not satisfied with current treatments according to new study

Patients with a serious type of inflammatory bowel disease, ulcerative colitis, are not satisfied with their current treatments and the majority do not have their disease under control, according to new research released today at the 9th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Copenhagen. The majority (87.2 per cent) of the 250 patients with moderate to severe ulcerative colitis who were being treated with standard therapies failed to achieve control of their disease – defined either as going into remission or not having needed to use corticosteroid medications in the previous two months.1 [More]
Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Children newly diagnosed with Crohn's disease may benefit from early treatment with the biologic drugs known as anti-TNF-α agents, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. [More]
Prosonix announces positive top-line results from PSX1002 Phase 2 study for COPD treatment

Prosonix announces positive top-line results from PSX1002 Phase 2 study for COPD treatment

Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces positive top-line results from its Phase 2 clinical study with PSX1002 in patients with moderate to severe chronic obstructive pulmonary disease. [More]
RoundTable Healthcare Partners sells Aqua Pharmaceuticals Holdings for $402.6M to Almirall

RoundTable Healthcare Partners sells Aqua Pharmaceuticals Holdings for $402.6M to Almirall

RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that it has completed the sale of Aqua Pharmaceuticals Holdings, Inc. to Almirall S.A. for up to $402.6 million in cash [More]
UT Southwestern receives $10M grant to find effective treatments for alcoholic hepatitis

UT Southwestern receives $10M grant to find effective treatments for alcoholic hepatitis

UT Southwestern Medical Center has launched the local arm of a national, multicenter study aimed at finding more effective treatments for alcoholic hepatitis, a disease of the liver that often leads to cirrhosis and death in severe cases. [More]

Research report on bone densitometers market

According to a new market report published by Transparency Market Research "Bone Densitometers Market(DEXA, QCT, pDEXA, SEXA, pQCT, RA and QUS)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global bone densitometers market was valued at USD 777.9 million in 2012 and is expected to grow at a CAGR of 3.3% from 2013 to 2019, to reach an estimated value of USD 908.5million in 2019. [More]

Evidence reveals bronchial thermoplasty has long-term benefit for asthma patients

​The beneficial effects of bronchial thermoplasty, a non-pharmacologic treatment for asthma, last at least five years, according to researchers at National Jewish Health and other institutions. [More]
Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease. [More]
Screening for genetic mutations may help identify silent carriers of adrenal Cushing's syndrome

Screening for genetic mutations may help identify silent carriers of adrenal Cushing's syndrome

Genetic research that will be published tomorrow in the New England Journal of Medicine suggests to Dr. André Lacroix, professor at the University of Montreal, that clinicians' understanding and treatment of a form of Cushing's syndrome affecting both adrenal glands will be fundamentally changed, and that moreover, it might be appropriate to begin screening for the genetic mutations that cause this form of the disease. [More]
Adding corticosteroid fluocortolone with standard therapy improves visual acuity in NAION patients

Adding corticosteroid fluocortolone with standard therapy improves visual acuity in NAION patients

Nonarteritic anterior ischemic optic neuropathy is one of the leading causes of sudden and irreversible loss of vision in older adults. In a prospective randomized trial of 60 patients with NAION, investigators have shown that the addition of the corticosteroid fluocortolone to standard therapy significantly improves both short- and long-term visual acuity, especially when given soon after the onset of symptoms. Their results are published in Restorative Neurology and Neuroscience. [More]
Researchers analyze benefits of platelet-rich plasma therapy for tennis elbow

Researchers analyze benefits of platelet-rich plasma therapy for tennis elbow

A procedure intended to help heal musculoskeletal injuries called platelet-rich plasma therapy, or P.R.P., has created a big buzz in sports medicine and the media in recent years. Tiger Woods reportedly received the procedure for a sore knee and Pittsburgh Steelers' Hines Ward used it for a sprained knee ligament just before playing a key role in the team's 2009 Super Bowl victory. [More]
Once-daily prescription medicine for COPD now available throughout the U.S.

Once-daily prescription medicine for COPD now available throughout the U.S.

GlaxoSmithKline plc and Theravance, Inc. today announced that BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease, is now available to pharmacies throughout the U.S. [More]

Research brings hope of new treatment for asthma patients resistant to corticosteroids

New research from Japan brings hope of a new treatment for asthma patients resistant to corticosteroids. In a study published today in the journal Nature Communications, researchers from the RIKEN Center for Integrative Medical Sciences and Keio University in Japan report that a type of lymphocytes called natural helper ells plays a critical role in corticosteroid resistance and demonstrate that the anti-psychotic drug Pimozide can be used to overcome resistance to steroids in severe asthma patients. [More]